Research Article
The Serum Concentrations of Chemokine CXCL12 and Its Specific Receptor CXCR4 in Patients with Esophageal Cancer
Table 2
Serum levels of proteins tested in patients with esophageal cancer in comparison with healthy controls.
| Group tested | CXCL12 (ng/mL) | CXCR4 (ng/mL) | CEA (ng/mL) | SCC-Ag (ng/mL) | CRP (ng/mL) |
| Control group () | Median (range) | 0.865 (0.105–4.297) | 0.932 (0.079–2.879) | 1.230 (0.500–4.540) | 1.000 (0.600–2.500) | 1.050 (0.200–10.900) |
| Esophageal cancer () Total group | Median (range) (EC versus healthy controls) | 1.277 (0.108–3.106)
| 0.443 (0.049–1.516)
| 2.220 (0.500–65.060)
| 1.200 (0.400–8.100) 0.567 | 6.500 (0.200–217.600)
|
| Adenocarcinoma of esophagus (AC) () | Median (range) (AC versus healthy controls) | 1.118 (0.108–2.697) 0.216 | 0.403 (0.049–1.516)
| 1.955 (0.500–46.550)
| 0.800 (0.400–2.200) 0.154 | 2.800 (0.200–46.800)
|
| Squamous cell cancer of esophagus (ESCC) () | Median (range) (ESCC versus healthy controls) (AC versus ESCC) | 1.501 (0.380–3.106) 0.562 | 0.534 (0.076–1.466) 0.146 0.168 | 2.250 (0.500–65.060) 0.904 | 1.400 (0.500–8.100)
| 14.900 (0.200–217.600)
|
|
|
Statistically significant when .
|